


Data Sheet

Product Name:	Repaglinide
Cat. No.:	CS-0979
CAS No.:	135062-02-1
Molecular Formula:	C ₂₇ H ₃₆ N ₂ O ₄
Molecular Weight:	452.59
Target:	Others
Pathway:	Others
Solubility:	DMSO : ≥ 50 mg/mL (110.48 mM)



BIOLOGICAL ACTIVITY:

Repaglinide is an **insulin secretagogue** for the treatment of type-2 diabetes mellitus^[1]. **In Vitro:** Repaglinide reduces postprandial glucose levels by enhancing the early phase of insulin secretion and increasing the total amount of insulin secreted^[1]. **In Vivo:** Repaglinide (AG-EE 623ZW) is very rapidly absorbed (t_{max} less than 1 hour) with a $t_{1/2}$ of less than one hour. Furthermore, Repaglinide is inactivated in the liver and more than 90 % excreted via the bile. Repaglinide (1 mg/kg p.o.) is effective ($P < 0.001$) as an insulin-releasing agent in a rat model (low-dose streptozotocin) of type 2 diabetes.

References:

[1]. Wang LC, et al. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus. *Medicine (Baltimore)*. 2018 Sep;97(38):e12476.

CAIndexNames:

Benzoic acid, 2-ethoxy-4-[2-[[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-

SMILES:

CC(C)C[C@H](NC(CC1=CC(OCC)=C(C(O)=O)C=C1)=O)C2=CC=CC=C2N3CCCCC3

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA